

PERFORMANCE IN DELIVERING CLINICAL RESEARCH – Q4 (2018/19)



IRAS No	REC No	Name of Trial	Target Number of Patients Agreed	Target Recruitment	Minimum No	Maximum No	Target Date to recruits patient agreed?	Date Agreed to recruit target number of patients	Total Recruited by agreed date	Total of Study Participants Recruited	Date closed to Recruitment	Reason for Closure
178129	15/EM/0400	CANC - 4158	Number Agreed	1	3	3	Date Agreed	30/08/2018	0	0	09/04/2018	Withdrawn by sponsor
137999	13/EE/0326	Revacept in Carotid Artery Stenosis	Number Agreed	5	5	5	Date Agreed	21/06/2018	14	14	14/05/2018	Recruitment Finished
192701	15/LO/1906	GAST 5150	Number Agreed	2	2	2	Date Agreed	02/03/2018	1	1	01/05/2018	Recruitment Finished
213166	16/EM/0436	AQ-03	Number Agreed	1	0	1	Date Agreed	31/12/2017	0	0	25/05/2018	Recruitment Finished
194313	16/LO/0581	CANC 5246	Number agreed	3	3	3	Date Agreed	31/12/2018	1	1	17/10/2018	Recruitment finished
183395	15/NE/0278	OPHT 4776	Number agreed	3	3	3	Date Agreed	19/04/2017	1	1	23/10/2018	Recruitment finished
198058	17/LO/0064	Study of Mirvetuximab Soravtansine vs standard cancer treatments	Number Agreed	2	1	2	Date Agreed	21/06/2018	1	1	26/04/2018	Recruitment finished
209261	16/SC/0600	Efficacy and Safety of Filgotinib in Active Ulcerative Colitis	Number Agreed	4	4	4	Date Agreed	30/09/2018	0	0	27/07/2018	Withdrawn by host
209260	16/SC/0601	Long Term Safety of Filgotinib in Active Ulcerative Colitis	Number Agreed	3	3	3	Date Agreed	30/11/2019	0	0	27/07/2018	Withdrawn by host
209259	16/SC/0630	Efficacy and Safety of Filgotinib in Active Crohn's Disease	Number Agreed	4	4	4	Date Agreed	31/12/2019	0	0	27/07/2018	Withdrawn by host
209258	16/SC/0631	Long Term Safety of Filgotinib in Active Crohn's Disease	Number Agreed	3	3	3	Date Agreed	30/11/2019	0	0	27/07/2018	Withdrawn by host
190690	16/EM/0193	CARD 4843	Number Agreed	6	6	6	Date Agreed	30/11/2018	6	6	15/12/2018	Recruitment finished
192397	16/YH/0083	CANC- 4997	Number Agreed	2	2	2	Date Agreed	26/09/2017	3	3	30/11/2018	Recruitment finished
222956	17/NE/0096	Sjögren's syndrome	Number Agreed	3	3	3	Date Agreed	31/12/2018	0	0	31/12/2018	Recruitment finished
242180	18/NW/0172	STEP 1 - Semaglutide Treatment Effect in People with obesity	Number Agreed	25	25	25	Date Agreed	02/11/2018	33	33	02/11/2018	Recruitment Finished
218606	17/EE/0196	SERENA	Number Agreed	20	20	20	Date Agreed	12/10/2018	21	21	12/10/2018	Recruitment Finished
148092	14/WS/1001	NCRN - 3244 - Masitinib + Gemcitabine VS Gemcitabine in Ovarian Cancer	Number Agreed	4	4	4	Date Agreed	15/05/2018	6	6	15/05/2018	Withdrawn by sponsor
213979	17/EM/0063	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study)	Number Agreed	1	1	1	Date Agreed	05/12/2017	0	0	04/03/2019	Recruitment finished